CryoCloud, an Utrecht, NL-based biotech company that provides a cryo-electron microscopy SaaS platform, has raised €2 million in Seed funding.
Investors
The round was led by Barcelona-based Nina Capital, with additional participation from Value Creation Capital, ROM Utrecht, and the Utrecht Health Seed Fund.
Nina Capital is a Barcelona-based venture capital firm founded in 2019, specializing in early-stage healthtech investments. The firm focuses on transforming healthcare through technology, with a particular emphasis on clinical innovation, healthcare infrastructure, and health data. Nina Capital has invested in over 50 companies across nearly 20 countries.
CryoCloud Use of Funds
The company will use the funds to advance its cloud-based cryo-EM platform, improve its machine-learning algorithms, and expand its capabilities to streamline drug development further.
About CryoCloud
Founded in 2021 by Robert Englmeier, Ilja Gubins, and Boy Persoon, CryoCloud offers cryo-electron microscopy (cryo-EM) SaaS platform designed to manage and process cryo-EM data efficiently. The platform provides researchers with cloud resources, image analysis workflows, and storage solutions for analyzing cryo-EM data and protein structures. CryoCloud's customer base spans over 25 countries, including users in academia, biotech, and the pharmaceutical industry.
Funding Details
Company: CryoCloud B.V.
Raised: €2.0M
Round: Seed
Funding Date: May 2025
Lead Investor: Nina Capital
Additional Investors: Value Creation Capital, ROM Utrecht, Utrecht Health Seed Fund
Company Website: https://www.cryocloud.io/
Software Category: Data Analysis and Cryo-Electron Microscopy
Source: https://tech.eu/2025/05/06/dutch-biotech-cryocloud-raises-2m-to-enhance-machine-learning-for-drug-discovery/